Skip to main content
SpringerLink
Log in

Endocrine therapy for advanced breast cancer: A review

  • Minisymposium
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

More than 45,000 women will die of metastatic breast cancer in the United States in 1991. Endocrine therapy remains a major option for treatment of such patients, and results in complete plus partial response rates of 30% with a median duration of approximately one year. Postmenopausal status, increased age, a prolonged disease-free interval, bone and soft tissue metastases, and positive estrogen and progesterone receptors are all associated with an increased response to endocrine therapy. The use of additive hormonal therapy, specifically antiestrogens, progestins, and aromatase inhibitors, have replaced surgical ablative procedures in the majority of patients; response rates to antiestrogen therapy, progestin therapy, and aromatase inhibitors are similar, but antiestrogens have generally been associated with the most favorable therapeutic index. At present, there is no convincing evidence that either combinations of endocrine therapies or endocrine therapy combined with chemotherapy are associated with an improvement in survival for patients with metastatic disease. Future research efforts directed at defining the molecular mechanisms of endocrine activity should facilitate clinical trials of newer and potentially more effective agents. All patients with metastatic breast cancer should be considered for at least one trial of endocrine therapy provided their metastatic disease is not rapidly progressive or life-threatening.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2:104–107, 1896

    Google Scholar 

  2. Ingle JN: Additive hormonal therapy in women with advanced breast cancer. Cancer 53:766–777, 1984

    PubMed  Google Scholar 

  3. Pritchard KI, Sutherland DJA: Diagnosis and therapy of breast cancer: The use of endocrine therapy. Hematol Oncol Clin North Am 3:765–805, 1989

    PubMed  Google Scholar 

  4. Miller WR: Endocrine treatment for breast cancers: biological rationale and current progress. J Steroid Biochem Molec Biol 37:467–480, 1990

    PubMed  Google Scholar 

  5. Henderson IC: Endocrine therapy of metastatic breast cancer.In Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. Lippincott, New York, 1991, pp 559–603

    Google Scholar 

  6. Manni A: Tamoxifen therapy of metastatic breast cancer. J Clin Lab Med 109:290–299, 1987

    Google Scholar 

  7. Petru E, Schmähl D: On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Klinische Wochenschrift 65:959–966, 1987

    PubMed  Google Scholar 

  8. Manni A, Santen RJ: Clinical use of aromatase inhibitors in the treatment of breast cancer [review]. Cancer Treat Res 39:67–81, 1988

    PubMed  Google Scholar 

  9. Brodie AM, Dowsett M, Coombes RC: Aromatase inhibitors as new endocrine therapy for breast cancer [review]. Cancer Treat Res 39:51–65, 1988

    PubMed  Google Scholar 

  10. Ingle JN: Principles of therapy in advanced breast cancer. Hematol Oncol Clin North Am 3:743–763, 1989

    PubMed  Google Scholar 

  11. Swain SE, Lippmann ME: Endocrine therapies of cancer.In Chabner BA, Collins JM (eds) Cancer Chemotherapy: Principles and Practice. Lippincott, Philadelphia, 1990, pp 59–109

    Google Scholar 

  12. Osborne CK: Receptors.In Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. Lippincott, Philadelphia, 1991, pp 301–325

    Google Scholar 

  13. van Netten JP, Algard FT, Coy P, Carlyle SJ, Brigden ML, Thornton KR, Peter S, Fraser T, To MP: Heterogeneous estrogen receptor levels detected via multiple microsamples from individual breast cancers. Cancer 56:2019–2024, 1985

    PubMed  Google Scholar 

  14. van Netten JP, Armstrong JB, Carlyle SJ, Goodchild NL, Thornton IG, Brigden ML, Coy P, Fletcher C: Cellular distribution patterns of estrogen receptor in human breast cancer. Eur J Cancer Clin Oncol 24:1899–1901, 1988

    PubMed  Google Scholar 

  15. Osborne CK: Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 12:317–326, 1985

    PubMed  Google Scholar 

  16. Iino Y, Gibson DF, Jordan VC: Antiestrogen therapy for breast cancer: current strategies and potential causes for therapeutic failure. Cancer Treat Res 53:221–237, 1991

    PubMed  Google Scholar 

  17. Lippman ME, Dickson RB: Growth control of normal and malignant breast epithelium. Prog Clin Biol Res 354A:147–178, 1990

    PubMed  Google Scholar 

  18. Epstein RJ: The clinical biology of hormone-responsive breast cancer. Cancer Treat Rev 15:33–51, 1988

    Google Scholar 

  19. Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC: Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39: 1447–1454, 1979

    PubMed  Google Scholar 

  20. Stewart JF, King RJ, Sexton SA, Millis RR, Rubens RD, Hayward JL: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17:449–453, 1981

    PubMed  Google Scholar 

  21. Beex LVAM, Koenders AJM: Is hormonal responsiveness in breast cancer age dependent? Rev Endocrine Related Cancer 19:5–10, 1984

    Google Scholar 

  22. O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Rubens RD, Richards MA: Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 8:2040–2046, 1990

    PubMed  Google Scholar 

  23. Osborne CK: Prognostic factors in breast cancer. Principles & Practice of Oncology: PPO Updates 4:1–11, 1990

    Google Scholar 

  24. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63:444–446, 1991

    PubMed  Google Scholar 

  25. Muss HB, Kute TE, Case LD, Smith LR, Booher C, Long R, Kammire L, Gregory B, Brockschmidt JK: The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 64:1894–1900, 1989

    PubMed  Google Scholar 

  26. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25:1165–1171, 1989

    PubMed  Google Scholar 

  27. Daidone MG, Silvestrini R, Valentinis B, Persici P, Mezzanotte G, Squicciarini P, Orefice S, Salvadori B: Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H]-thymidine labelling index. Cell Tissue Kinetics 23:401–408, 1990

    Google Scholar 

  28. Wilson AJ: Response in breast cancer to a second hormonal therapy. Rev Endocrine Rev Endocrine Related Cancer 14:5–11, 1983

    Google Scholar 

  29. Taylor SG, Gelman RS, Falkson G, Cummings FJ: Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Annals Intern Med 104:455–461, 1986

    Google Scholar 

  30. Anonymous: A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 4:186–193, 1986

  31. Binder SC, Flynn WJ, Pass LM: Endocrine ablative therapy of metastatic breast cancer. Ca 27:1–9, 1977

    Google Scholar 

  32. Nemoto T, Patel J, Rosner D, Dao TL: Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer. Cancer 53:1333–1335, 1984

    PubMed  Google Scholar 

  33. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545–551, 1981

    PubMed  Google Scholar 

  34. Kiang DT, Frenning DH, Vosika GJ, Kennedy BJ: Comparison of tamoxifen and hypophysectomy in breast cancer treatment. Cancer 45:1322–1325, 1980

    PubMed  Google Scholar 

  35. Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS, Lipton A: A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43:2207–2214, 1979

    PubMed  Google Scholar 

  36. Manni A: Tamoxifen therapy of metastatic breast cancer. J Lab Clin Med 109:290–299, 1987

    PubMed  Google Scholar 

  37. Canney PA, Griffiths T, Latief TN, Priestman TJ: Clinical significance of tamoxifen withdrawal response [letter]. Lancet i:36, 1987

    Google Scholar 

  38. Pommier RF, Woltering EA, Keenan EJ, Fletcher WS: The mechanism of hormone-sensitive breast cancer progression on antiestrogen therapy. Implications for treatment and protocol planning. Arch Surg 122:1311–1316, 1987

    PubMed  Google Scholar 

  39. Clarysse A: Hormone-induced tumor flare [editorial]. Eur J Cancer Clin Oncol 21:545–547, 1985

    PubMed  Google Scholar 

  40. Plotkin D, Lechner JJ, Jung WE, Rosen PJ: Tamoxifen flare in advanced breast cancer. JAMA 240:2644–2646, 1978

    PubMed  Google Scholar 

  41. Valavaara R: Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat 16 (Suppl):S31-S35, 1990

    PubMed  Google Scholar 

  42. Bellmunt J, Sole L: European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 14 (Suppl 2):36–39, 1991

    PubMed  Google Scholar 

  43. Witte RS, Pruitt B, Tormey DC, Moss S, Rose DP, Falkson G, Carbone PP, Ramirez G, Falkson H, Pretorius FJ: A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects. Cancer 57:34–39, 1986

    PubMed  Google Scholar 

  44. Löber J, Rose C, Salimtschik M, Mouridsen HT: Treatment of advanced breast cancer with progestins. Acta Obstet Gynecol Scand (Suppl) 101:39–46, 1981

    Google Scholar 

  45. Haller DG, Glick JH: Progestational agents in advanced breast cancer: an overview. Semin Oncol 13:2–8, 1986

    PubMed  Google Scholar 

  46. Pannuti F, Martoni A, Piana E, Guaraldi M: Progestins in breast cancer.In Pannuti F (ed) Hormonotherapy: Results and Perspectives. Edizioni, 1988, p. 207–222.

  47. Sedlacek SM, Horwitz KB: The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids 44:467–483, 1991

    Google Scholar 

  48. Pannuti F, Martoni A, Di Marco AR, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra GA, Persiani W, Cacciari L, Spagnolo F, Palenzona D, Rocchetta G: Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15:593–601, 1979

    PubMed  Google Scholar 

  49. Della Cuna GR, Calciati A, Strada MRB, Bumma C, Campio L: High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori 64:143–149, 1978

    PubMed  Google Scholar 

  50. Cortes Funes H, Madrigal PL, Perez Mangas G, Mendiola C: Medroxyprogesterone acetate at two different doses for the treatment of advanced breast cancer.In Campio L, Robustelli Della Cuna G, Taylor RW (eds) Role of Medroxyprogesterone in Endocrine Related Tumors. Raven Press, New York, 1983, pp 77–83

    Google Scholar 

  51. Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Alberto P: Randomized trial of low- versus highdose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2:414–41, 1984

    PubMed  Google Scholar 

  52. Gallagher CJ, Cairnduff F, Smith IE: High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 23:1895–1900, 1987

    PubMed  Google Scholar 

  53. Sedlacek SM: An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 15:3–13, 1988

    Google Scholar 

  54. Tchekmedyian NS, Tait N, Abrams J, Aisner J: High-dose megestrol acetate in the treatment of advanced breast cancer. Semin Oncol 15:44–49, 1988

    PubMed  Google Scholar 

  55. Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, Richards F, Powell BL, Spurr CL, White D, et al: High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 8: 1797–1805, 1990

    PubMed  Google Scholar 

  56. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG: Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37:789–794, 1990

    PubMed  Google Scholar 

  57. Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E, Wells SA: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Annals Intern Med 96:94–101, 1982

    Google Scholar 

  58. Stuart-Harris RC, Smith IE: Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 11:189–204, 1984

    PubMed  Google Scholar 

  59. Wander HE, Blossey HC, Nagel GA: Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer Clin Oncol 22:1371–1374, 1986

    PubMed  Google Scholar 

  60. Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, Buzdar AU, Nagel GA, Henderson IC: Aminoglutethimide-induced hematologic toxicity: worldwide experience. Cancer Treat Rep 69:1003–1004, 1985

    PubMed  Google Scholar 

  61. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A: 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet ii:1237–1239, 1984

    Google Scholar 

  62. Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AM, Gazet JC, Coombes RC: Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 46:4823–4826, 1986

    PubMed  Google Scholar 

  63. Beardwell GG, Hindley AC, Wilkinson PM, Todd IDH, Ribeiro GG, Bu'Lock D: Trilostane in the treatment of advanced breast cancer. Cancer Chemother Pharmacol 10:158–160, 1983

    PubMed  Google Scholar 

  64. Coombes RC, Powles TJ, Muindi J, Hunt J, Ward M, Perez D, Neville AM: Trilostane therapy for advanced breast cancer. Cancer Treat Rep 69:351–354, 1985

    PubMed  Google Scholar 

  65. Williams CJ, Barley V, Blackledge G, Hutcheon A, Kaye S, Smith D, Keen C, Webster DJ, Rowland C, Tyrrell C: Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. Cancer Treat Rep 71:1197–1201, 1987

    PubMed  Google Scholar 

  66. Sonino N: The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317:812–818, 1987

    PubMed  Google Scholar 

  67. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR: Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 237:2079–2078, 1977

    PubMed  Google Scholar 

  68. Minton MJ, Knight RK, Rubens RD, Hayward JL: Corticosteroids for elderly patients with breast cancer. Cancer 48:883–887, 1981

    PubMed  Google Scholar 

  69. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R: Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751–754, 1985

    PubMed  Google Scholar 

  70. Coombes RC, Dearnaley D, Humphreys J, Gazet JC, Ford HT, Nash AG, Mashiter K, Powles TJ: Danazol treatment of advanced breast cancer. Cancer Treat Rep 64:1073–1076, 1980

    PubMed  Google Scholar 

  71. Coombes RC, Perez D, Gazet JC, Ford HT, Powles TJ: Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 10:194–195, 1983

    PubMed  Google Scholar 

  72. Brodovsky HS, Holroyde CP, Laucius JF, Dugery C, Serbin J: Danazol in the treatment of women with metastatic breast cancer. Cancer Treat Rep 71:875–876, 1987

    PubMed  Google Scholar 

  73. Pronzato P, Amoroso D, Ardizzoni A, Bertelli G, Conte PF, Michelotti A, Rosso R: A phase II study of danazol in metastatic breast cancer. Am J Clin Oncol 10:407–409, 1987

    PubMed  Google Scholar 

  74. Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA: Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 6:207–210, 1988

    PubMed  Google Scholar 

  75. Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI: The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53:629–636, 1986

    PubMed  Google Scholar 

  76. Minton JP: The response of breast cancer patients with bone pain to L-DOPA. Cancer 33:358–363, 1974

    PubMed  Google Scholar 

  77. Holtkamp W, Nagel GA: Bromocriptine in chemotherapy-resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO Study [Ger]. Onkologie 11:121–127, 1988

    PubMed  Google Scholar 

  78. Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M: Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 14:289–298, 1989

    PubMed  Google Scholar 

  79. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE, et al: Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 67:886–891, 1991

    PubMed  Google Scholar 

  80. Kiang DT, Gay J, Goldman A, Kennedy BJ: A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 313:1241–1246, 1985

    PubMed  Google Scholar 

  81. Hug V, Hortobagyi GN, Drewinko B, Finders M: Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 3:1672–1677, 1985

    PubMed  Google Scholar 

  82. Hug V, Thames H, Clark J: Chemotherapy and hormonal therapy in combination. J Clin Oncol 6:173–177, 1988

    PubMed  Google Scholar 

  83. Muss HB, Smith LR, Cooper MR: Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. J Clin Oncol 5:1556–1558, 1987

    PubMed  Google Scholar 

  84. Dorr RT, Fritz WL: Cancer Chemotherapy Handbook. Elsevier, New York, 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Cancer Center of Wake Forest University, and the Bowman Gray School of Medicine, 27157, Winston-Salem, NC, USA

    Hyman B. Muss M.D.

Authors
  1. Hyman B. Muss M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Held at the 14th Annual San Antonio Breast Cancer Symposium, December 5, 1991, and supported by an educational grant from Bristol-Myers Oncology Division, Evansville IN, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muss, H.B. Endocrine therapy for advanced breast cancer: A review. Breast Cancer Res Tr 21, 15–26 (1992). https://doi.org/10.1007/BF01811960

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01811960

Key words

Search

Navigation